Results 11 to 20 of about 14,825 (199)

Current perspectives on lipid management in diabetic kidney disease: Can fibrates offer advantages over statins for renal outcomes? [PDF]

open access: yesJournal of Research in Medical Sciences
Diabetic kidney disease (DKD) affects 30%–40% of patients with diabetes mellitus (DM). Dyslipidemia is a key modifiable risk factor for the development and progression of DKD.
Mohammad Reza Chitsazi   +9 more
doaj   +3 more sources

Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses [PDF]

open access: yesFrontiers in Pharmacology
BackgroundPrimary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive cholestasis. Although ursodeoxycholic acid (UDCA) is the standard therapy, a substantial proportion of patients show inadequate response ...
Jian Zhang, Ting Xiu, Qi Shen
doaj   +2 more sources

Exploring the mechanism of fibrates regulating HIF-1A in the treatment of ischemic stroke based on network pharmacology and molecular docking

open access: yesBMC Research Notes
Fibrates can prevent and treat ischemic stroke (IS), the occurrence and development of IS is closely related to hypoxia-inducible factor-1A (HIF-1A). However, the exact mechanism by which fibrates regulate HIF-1A to treat IS remains unclear.
Fengjiao Yang   +8 more
doaj   +2 more sources

Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention [PDF]

open access: yesBMC Neurology, 2013
Background Fibrates has been extensively used to improve plasma lipid levels and prevent adverse cardiovascular outcomes. However, the effect of fibrates on stroke is unclear at the present time. We therefore carried out a comprehensive systematic review
Zhou Yu-Hao   +6 more
doaj   +3 more sources

Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study [PDF]

open access: yesFrontiers in Pharmacology, 2022
Aim: Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the addition of fibrates.
Guilherme Grossi Lopes Cançado   +23 more
doaj   +2 more sources

Lagrangian Fibrations

open access: yesMilan Journal of Mathematics, 2022
AbstractWe review the theory of Lagrangian fibrations of hyperkähler manifolds as initiated by Matsushita. We also discuss more recent work of Shen–Yin and Harder–Li–Shen–Yin. Occasionally, we give alternative arguments and complement the discussion by additional observations.
D. Huybrechts, M. Mauri
openaire   +4 more sources

Latent Fibrations: Fibrations for Categories of Partial Maps

open access: yesTheory and Applications of Categories, 2021
65 pages, submitted to "Theory and Applications of Categories"
Cockett, Robin   +3 more
openaire   +3 more sources

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

open access: yes, 2021
INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid.
Albillos, Agustin   +30 more
core   +2 more sources

The Gödel Fibration

open access: yes, 2021
39 ...
Davide Trotta   +2 more
openaire   +4 more sources

Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression [PDF]

open access: yes, 2009
In this study, we investigated the effects of statins, fibrates, 9-cis-retinoic acid and forskolin on the transcription of the mitochondrial carnitine/acylcarnitine carrier (CAC) gene.
Iacobazzi V   +5 more
core   +3 more sources

Home - About - Disclaimer - Privacy